APA (7th ed.) Citation

Niehr, F., Weichert, W., & Stenzinger, A. (2015). CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. BioMed Central.

Chicago Style (17th ed.) Citation

Niehr, Franziska, Wilko Weichert, and Albrecht Stenzinger. CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells with Acquired Resistance to Cisplatin or Cetuximab. London: BioMed Central, 2015.

MLA (9th ed.) Citation

Niehr, Franziska, et al. CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells with Acquired Resistance to Cisplatin or Cetuximab. BioMed Central, 2015.